Drugs / Selenomethionine

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT01211561 Dec 2010 → Dec 2014 colorectal cancer University of Illinois at Chicago Unknown No outcome recorded
Phase 11 trial
Phase 1 NCT04952129 May 2022 → Dec 2023 colorectal adenoma University of Auckland, New Zealand Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05363631 Sep 2022 → Dec 2026 expected clear cell renal carcinoma Mohammed Milhem Active not recruiting No outcome recorded
Phase 1/2 NCT02535533 Jan 2016 → Aug 2023 clear cell renal carcinoma Mohammed Milhem Completed No outcome recorded
Phase 22 trials
Phase 2 NCT01682031 Jun 2009 → Apr 2012 chemotherapy-induced toxicity, hypopharynx squamous cell carcinoma, laryngeal squamous cell carcinoma, lip and oral cavity squamous cell carcinoma +5 Roswell Park Cancer Institute Terminated No outcome recorded
Phase 2 NCT00455416 Apr 2007 → Apr 2009 follicular lymphoma Oslo University Hospital Unknown No outcome recorded
Phase not applicable2 trials
NCT00271427 Dec 2004 → Aug 2005 Hashimoto thyroiditis Ege University Completed No outcome recorded
NCT00212186 Oct 1998 → Nov 2003 cirrhosis of liver Vanderbilt University Completed No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT07427017 Comparator Apr 2026 → Dec 2028 expected ulcerative colitis Northwestern University Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT00030901 Comparator Feb 2000 → Nov 2011 preneoplastic lesion, prostate cancer SWOG Cancer Research Network Completed No outcome recorded

Evidence & citations 13 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as selenomethionine “Patients and controls were randomly assigned to one of 3 treatment groups: 200 µg selenium per day as selenate, 200 µg selenium per day as selenomethionine, or a placebo.” NCT00212186
6

“Patients receive selenomethionine PO twice daily in week 1 and then once daily in weeks 2-11.” NCT01682031

“Patients enrolled in the study will receive 200 mcg selenomethionine daily” NCT07427017

NCT02535533

NCT05363631

NCT01211561

NCT04952129

Known as 75se ChEMBL registry synonym — accepted as the source's own label CHEMBL113178
Known as L-Selenomethionine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00455416
2

NCT00271427

NCT00030901

Known as NSC-760370 ChEMBL registry synonym — accepted as the source's own label CHEMBL113178
Known as Radioselenomethionine 75 se ChEMBL registry synonym — accepted as the source's own label CHEMBL113178
Known as Selenomethionine (75se) injection ChEMBL registry synonym — accepted as the source's own label CHEMBL113178
Known as Selenomethionine, l-, se-75 ChEMBL registry synonym — accepted as the source's own label CHEMBL113178
Known as Selenomethionine, se-75 ChEMBL registry synonym — accepted as the source's own label CHEMBL113178
Known as Selenometionina (75se) ChEMBL registry synonym — accepted as the source's own label CHEMBL113178
Known as SLM “Drug: Selenomethionine (SLM)” NCT05363631
1

“Selenomethionine (SLM)” NCT02535533

Action Inhibit “L-selenomethionine may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth.” NCT02535533
Modality Other / unclassified “Seleno-amino acid” NCT04952129
Route Oral “L-selenomethionine (Selenium)one tablet by mouth daily for 3 years.” NCT00030901